Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics Inc (CYTK) and DBV Technologies SA – American (DBVT).
Cytokinetics Inc (CYTK)
Needham analyst Chad Messer reiterated a Buy rating on Cytokinetics Inc today and set a price target of $16.00. The company’s shares closed last Monday at $11.41.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 5.1% and a 40.7% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Autolus Therapeutics Plc, and Sarepta Therapeutics.
Currently, the analyst consensus on Cytokinetics Inc is a Strong Buy with an average price target of $20.17, representing a 74.0% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $26.00 price target.
See today’s analyst top recommended stocks >>
DBV Technologies SA – American (DBVT)
Stifel Nicolaus analyst Derek Archila reiterated a Hold rating on DBV Technologies SA – American today. The company’s shares closed last Monday at $9.15.
According to TipRanks.com, Archila has currently no stars on a ranking scale of 0-5 stars, with an average return of -13.1% and a 24.5% success rate. Archila covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and NGM Biopharmaceuticals Inc.
DBV Technologies SA – American has an analyst consensus of Moderate Buy.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
